Jan 21, 2026 08:00AM
Jan 20, 2026 12:01PM
Jan 12, 2026 08:00AM
Dec 21, 2025 04:00AM
Dec 8, 2025 02:54AM
Dec 6, 2025 02:00PM
Nov 12, 2025 07:00AM Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
Nov 6, 2025 04:00PM
Nov 3, 2025 11:05AM
Oct 21, 2025 07:00AM
Oct 20, 2025 07:43AM
Sep 25, 2025 08:00AM
Sep 11, 2025 08:18AM
Sep 10, 2025 09:16AM RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
Aug 11, 2025 07:00AM
Jul 16, 2025 12:38PM
Jul 2, 2025 06:38AM
Jun 3, 2025 10:45AM
Jun 3, 2025 10:45AM
May 22, 2025 05:25PM
May 22, 2025 05:15PM Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
May 22, 2025 05:15PM
Apr 12, 2025 04:00AM
Apr 11, 2025 09:44AM
Mar 4, 2025 08:00AM
Jan 2, 2025 07:00AM
Dec 22, 2024 04:00AM
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 9, 2024 07:35PM
Nov 12, 2024 08:00AM
Nov 5, 2024 09:10AM
Nov 4, 2024 07:32AM
Nov 4, 2024 07:30AM
Oct 15, 2024 02:15PM
Sep 27, 2024 04:35PM CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
Sep 14, 2024 06:53PM
Aug 28, 2024 06:40AM
Aug 9, 2024 09:00AM
Jul 12, 2024 01:45PM
Jul 2, 2024 08:00AM
Jul 2, 2024 08:00AM
Jun 3, 2024 04:00PM Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
May 31, 2024 05:30AM
May 23, 2024 05:00PM
May 14, 2024 04:05PM
May 13, 2024 07:00AM
Apr 22, 2024 01:07PM
Apr 22, 2024 01:05PM
Apr 5, 2024 11:30PM Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Mar 15, 2024 03:16PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All